Article thumbnail

Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab

By Marc E. Rothenberg, Amy D. Klion, Florence E. Roufosse, Jean Emmanuel Kahn, Peter Fahey Weller, Hans-Uwe Simon, Lawrence B. Schwartz, Lanny J. Rosenwasser, Johannes Ring, Elaine F. Griffin, Ann E. Haig, Paul I.H. Frewer, Jacqueline M. Parkin and Gerald J. Gleich

Abstract

The hypereosinophilic syndrome is a group of diseases characterized by persistent blood eosinophilia, defined as more than 1500 cells per microliter with end-organ involvement and no recognized secondary cause. Although most patients have a response to corticosteroids, side effects are common and can lead to considerable morbidity

Publisher: 'Massachusetts Medical Society'
Year: 2016
DOI identifier: 10.1056/nejmoa070812.
OAI identifier: oai:dash.harvard.edu:1/28702415
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://nrs.harvard.edu/urn-3:H... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.